BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5400
- TODAY'S CHANGE (%)0.0039 (0.7275%)
- Bid / Lots0.5401/ 5
- Ask / Lots0.5800/ 50
- Open / Previous Close0.5990 / 0.5361
- Day Range
- 52 Week Range
- Volume344,863
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 9127 | 0.5926 |
| 09:34 ET | 100 | 0.5897 |
| 09:36 ET | 9315 | 0.59 |
| 09:38 ET | 2600 | 0.59 |
| 09:39 ET | 5016 | 0.59005 |
| 09:41 ET | 17333 | 0.5889 |
| 09:45 ET | 8403 | 0.587 |
| 09:48 ET | 2597 | 0.5869 |
| 09:50 ET | 1175 | 0.587 |
| 09:52 ET | 100 | 0.574 |
| 09:56 ET | 100 | 0.5701 |
| 10:03 ET | 2600 | 0.5701 |
| 10:06 ET | 500 | 0.57 |
| 10:14 ET | 300 | 0.5629 |
| 10:15 ET | 5000 | 0.5599 |
| 10:17 ET | 2829 | 0.552 |
| 10:19 ET | 700 | 0.5525 |
| 10:21 ET | 3100 | 0.5525 |
| 10:26 ET | 3671 | 0.5599 |
| 10:28 ET | 300 | 0.555 |
| 10:30 ET | 500 | 0.555 |
| 10:32 ET | 100 | 0.5501 |
| 10:33 ET | 936 | 0.5553 |
| 10:42 ET | 2000 | 0.552101 |
| 10:46 ET | 100 | 0.552 |
| 10:53 ET | 100 | 0.553 |
| 10:57 ET | 20181 | 0.5527 |
| 11:02 ET | 300 | 0.552 |
| 11:04 ET | 6225 | 0.554768 |
| 11:06 ET | 5000 | 0.5549 |
| 11:08 ET | 300 | 0.551 |
| 11:09 ET | 11020 | 0.5478 |
| 11:11 ET | 2976 | 0.5415 |
| 11:13 ET | 900 | 0.54 |
| 11:18 ET | 100 | 0.5415 |
| 11:20 ET | 100 | 0.546688 |
| 11:24 ET | 7891 | 0.54 |
| 11:27 ET | 200 | 0.54 |
| 11:31 ET | 400 | 0.5475 |
| 11:36 ET | 800 | 0.541 |
| 11:38 ET | 1000 | 0.5474 |
| 11:40 ET | 600 | 0.542 |
| 11:42 ET | 100 | 0.54 |
| 11:44 ET | 1959 | 0.547499 |
| 11:49 ET | 4601 | 0.544499 |
| 11:51 ET | 100 | 0.5445 |
| 12:00 ET | 2800 | 0.547 |
| 12:02 ET | 100 | 0.547 |
| 12:03 ET | 200 | 0.5445 |
| 12:05 ET | 220 | 0.542 |
| 12:20 ET | 700 | 0.542 |
| 12:21 ET | 18450 | 0.5468 |
| 12:23 ET | 200 | 0.5432 |
| 12:25 ET | 100 | 0.542 |
| 12:27 ET | 300 | 0.542 |
| 12:48 ET | 700 | 0.5425 |
| 12:50 ET | 600 | 0.5466 |
| 12:54 ET | 1200 | 0.5466 |
| 12:56 ET | 7068 | 0.5453 |
| 12:59 ET | 200 | 0.542 |
| 01:01 ET | 160 | 0.542 |
| 01:21 ET | 100 | 0.5464 |
| 01:28 ET | 125 | 0.5442 |
| 01:30 ET | 200 | 0.5464 |
| 01:32 ET | 5000 | 0.5442 |
| 01:33 ET | 4936 | 0.54 |
| 01:35 ET | 369 | 0.54 |
| 01:37 ET | 5100 | 0.54 |
| 01:39 ET | 200 | 0.54 |
| 01:44 ET | 100 | 0.54 |
| 01:48 ET | 2255 | 0.5401 |
| 01:55 ET | 100 | 0.5401 |
| 02:08 ET | 4157 | 0.54 |
| 02:09 ET | 8443 | 0.5401 |
| 02:11 ET | 587 | 0.54 |
| 02:13 ET | 2200 | 0.5401 |
| 02:15 ET | 500 | 0.54005 |
| 02:22 ET | 100 | 0.54 |
| 02:26 ET | 2308 | 0.54 |
| 02:33 ET | 949 | 0.54 |
| 02:36 ET | 100 | 0.54 |
| 02:40 ET | 3000 | 0.5401 |
| 02:42 ET | 300 | 0.54 |
| 02:44 ET | 100 | 0.54 |
| 02:45 ET | 100 | 0.5401 |
| 02:51 ET | 2000 | 0.5401 |
| 02:56 ET | 100 | 0.54 |
| 03:16 ET | 100 | 0.5401 |
| 03:25 ET | 6500 | 0.5401 |
| 03:27 ET | 5970 | 0.5401 |
| 03:32 ET | 3200 | 0.5401 |
| 03:36 ET | 1100 | 0.54005 |
| 03:38 ET | 100 | 0.54 |
| 03:39 ET | 2387 | 0.5401 |
| 03:41 ET | 500 | 0.5401 |
| 03:45 ET | 6753 | 0.54 |
| 03:48 ET | 6700 | 0.54 |
| 03:50 ET | 100 | 0.54 |
| 03:52 ET | 600 | 0.54 |
| 03:56 ET | 7344 | 0.54 |
| 03:57 ET | 3400 | 0.54009 |
| 03:59 ET | 1400 | 0.54 |
Sep 17, 2024
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection, from 1:01PM ET on Tuesday Sep 17, 2024 by Dow Jones
1:01PM ET on Tuesday Sep 17, 2024 by Dow Jones
Sep 4, 2024
DJ BioLine RX Initiated at Buy by Jones Trading, from 12:15PM ET on Wednesday Sep 04, 2024 by Dow Jones
12:15PM ET on Wednesday Sep 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 52.6M | -0.7x | --- |
Cue Biopharma Inc | 45.6M | -0.7x | --- |
Kronos Bio Inc | 60.3M | -0.6x | --- |
Kezar Life Sciences Inc | 56.4M | -0.6x | --- |
LAVA Therapeutics NV | 43.6M | -1.9x | --- |
Adlai Nortye Ltd | 73.2M | -0.3x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $52.6M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 80.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.46 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 4.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
